Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.
2.

Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron.

Powers JM, Shamoun M, McCavit TL, Adix L, Buchanan GR.

J Pediatr. 2017 Jan;180:212-216. doi: 10.1016/j.jpeds.2016.09.053. Epub 2016 Oct 21.

PMID:
27776750
3.

Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.

Morris CR, Kim HY, Klings ES, Wood J, Porter JB, Trachtenberg F, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Hassell K, Taher A, Neufeld EJ, Thompson AA, Larkin S, Suh JH, Vichinsky EP, Kuypers FA; Thalassemia Clinical Research Network.

Br J Haematol. 2015 Jun;169(6):887-98. doi: 10.1111/bjh.13452. Epub 2015 Apr 24.

4.

Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload.

Aygun B, Mortier NA, Kesler K, Lockhart A, Schultz WH, Cohen AR, Alvarez O, Rogers ZR, Kwiatkowski JL, Miller ST, Sylvestre P, Iyer R, Lane PA, Ware RE; Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) Trial Investigators.

Br J Haematol. 2015 Apr;169(2):262-6. doi: 10.1111/bjh.13280. Epub 2015 Jan 22.

5.

Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.

Helton KJ, Adams RJ, Kesler KL, Lockhart A, Aygun B, Driscoll C, Heeney MM, Jackson SM, Krishnamurti L, Miller ST, Sarnaik SA, Schultz WH, Ware RE; SWiTCH Investigators.

Blood. 2014 Aug 7;124(6):891-8. doi: 10.1182/blood-2013-12-545186. Epub 2014 Jun 9.

6.

Relationship among chelator adherence, change in chelators, and quality of life in thalassemia.

Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, Thompson AA, Neufeld EJ, Yamashita R; Thalassemia Clinical Research Network.

Qual Life Res. 2014 Oct;23(8):2277-88. doi: 10.1007/s11136-014-0671-2. Epub 2014 Mar 30.

7.

Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).

Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30.

8.

Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.

Morris CR, Kim HY, Wood J, Porter JB, Klings ES, Trachtenberg FL, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Singer ST, Taher A, Neufeld EJ, Thompson AA, Sachdev V, Larkin S, Suh JH, Kuypers FA, Vichinsky EP; Thalassemia Clinical Research Network.

Haematologica. 2013 Sep;98(9):1359-67. doi: 10.3324/haematol.2012.082065. Epub 2013 Apr 12.

9.

Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS).

Neunert CE, Buchanan GR, Imbach P, Bolton-Maggs PH, Bennett CM, Neufeld E, Vesely SK, Adix L, Blanchette VS, K├╝hne T; Intercontinental Cooperative ITP Study Group Registry II Participants.

Blood. 2013 May 30;121(22):4457-62. doi: 10.1182/blood-2012-12-466375. Epub 2013 Apr 2.

10.

Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial.

Kalpatthi R, Thompson B, Lu M, Wang WC, Patel N, Kutlar A, Howard T, Luchtman-Jones L, Miller ST; BABY HUG Investigators.

Clin Biochem. 2013 Feb;46(3):278-81. doi: 10.1016/j.clinbiochem.2012.10.032. Epub 2012 Oct 31.

11.

Inadequate dietary intake in patients with thalassemia.

Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichinsky EP; Thalassemia Clinical Research Network.

J Acad Nutr Diet. 2012 Jul;112(7):980-90. doi: 10.1016/j.jand.2012.01.017. Epub 2012 May 1.

12.

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

Ware RE, Helms RW; SWiTCH Investigators.

Blood. 2012 Apr 26;119(17):3925-32. doi: 10.1182/blood-2011-11-392340. Epub 2012 Feb 7.

13.

Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.

Alvarez O, Miller ST, Wang WC, Luo Z, McCarville MB, Schwartz GJ, Thompson B, Howard T, Iyer RV, Rana SR, Rogers ZR, Sarnaik SA, Thornburg CD, Ware RE; BABY HUG Investigators.

Pediatr Blood Cancer. 2012 Oct;59(4):668-74. doi: 10.1002/pbc.24100. Epub 2012 Jan 31.

14.

Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network.

Blood. 2012 Mar 22;119(12):2746-53. doi: 10.1182/blood-2011-04-344507. Epub 2012 Jan 25.

15.

Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities.

Aygun B, Wruck LM, Schultz WH, Mueller BU, Brown C, Luchtman-Jones L, Jackson S, Iyer R, Rogers ZR, Sarnaik S, Thompson AA, Gauger C, Helms RW, Ware RE; TCD With Transfusions Changing to Hydroxyurea (TWiTCH) Trial Investigators.

Am J Hematol. 2012 Apr;87(4):428-30. doi: 10.1002/ajh.23105. Epub 2012 Jan 9. No abstract available.

16.

Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report.

Morris CR, Kim HY, Trachtenberg F, Wood J, Quinn CT, Sweeters N, Kwiatkowski JL, Thompson AA, Giardina PJ, Boudreaux J, Olivieri NF, Porter JB, Neufeld EJ, Vichinsky EP; Thalassemia Clinical Research Network.

Blood. 2011 Oct 6;118(14):3794-802. doi: 10.1182/blood-2010-11-319152. Epub 2011 Jul 19.

17.

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators.

Lancet. 2011 May 14;377(9778):1663-72. doi: 10.1016/S0140-6736(11)60355-3.

18.

Renal dysfunction in patients with thalassaemia.

Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirby M, Giardina PJ; Thalassemia Clinical Research Network.

Br J Haematol. 2011 Apr;153(1):111-7. doi: 10.1111/j.1365-2141.2010.08477.x. Epub 2011 Feb 21.

19.

Red cell alloimmunization in a diverse population of transfused patients with thalassaemia.

Thompson AA, Cunningham MJ, Singer ST, Neufeld EJ, Vichinsky E, Yamashita R, Giardina P, Kim HY, Trachtenberg F, Kwiatkowski JL; Thalassemia Clinical Research Network Investigators.

Br J Haematol. 2011 Apr;153(1):121-8. doi: 10.1111/j.1365-2141.2011.08576.x. Epub 2011 Feb 17.

20.

Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial.

Rogers ZR, Wang WC, Luo Z, Iyer RV, Shalaby-Rana E, Dertinger SD, Shulkin BL, Miller JH, Files B, Lane PA, Thompson BW, Miller ST, Ware RE; BABY HUG.

Blood. 2011 Mar 3;117(9):2614-7. doi: 10.1182/blood-2010-04-278747. Epub 2011 Jan 7.

Supplemental Content

Loading ...
Support Center